|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | DAPAGLIFLOZIN: FOR THE TREATMENT OF TYPE - 2 DIABETES |
| Authors Name: | Vahadane Ruchika Sheshrao , Wagh Pratik Laxman , Bhawar Sanjay. B |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_213202
|
| Published Paper Id: | IJNRD2401317 |
| Published In: | Volume 9 Issue 1, January-2024 |
| DOI: | |
| Abstract: | Dapagliflozin ( Forxiga®) is a globally recognized treatment for type 2 diabetes, known for its high potency, reversibility, and selectivity as a sodium-glucose cotransporter-2 inhibitor. Dapagliflozin, taken orally once daily, is approved in the EU for use as monotherapy (in patients intolerant of metformin) and as an add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone are insufficient for adequate glycemic control. Dapagliflozin, whether used alone or in combination with other Antihyperglycemic agents, demonstrated effective glycemic control and led to reductions in body weight and blood pressure in a wide range of patients, as evidenced by numerous meticulously conducted clinical studies and their extensions. Dapagliflozin decreased the occurrence of cardiovascular (CV) death or hospitalization for heart failure (HHF), showed no negative impact on major adverse CV events (MACE), and potentially slowed the progression of renal disease compared to a placebo in individuals with confirmed atherosclerotic CV disease (CVD) or multiple CVD risk factors. Dapagliflozin was generally well received, exhibiting a minimal risk of hypoglycemia. While diabetic ketoacidosis (DKA), though infrequent, genital infections were more prevalent with dapagliflozin compared to the placebo. Due to its antihyperglycemic, cardioprotective, and potentially reno protective attributes, along with a generally well-tolerated profile, dapagliflozin emerges as a significant choice for treating a Adiverse range of patients, irrespective of their cardiovascular history. |
| Keywords: | Dapagliflozin, Type 2 diabetes, cardiovascular disease, Adverse event. |
| Cite Article: | "DAPAGLIFLOZIN: FOR THE TREATMENT OF TYPE - 2 DIABETES", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 1, page no.d130-d139, January-2024, Available :http://www.ijnrd.org/papers/IJNRD2401317.pdf |
| Downloads: | 000118756 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2401317 Registration ID: 213202 Published In: Volume 9 Issue 1, January-2024 DOI (Digital Object Identifier): Page No: d130-d139 Country: Ahemadnagar, MAHARASHTRA, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2401317 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2401317 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn